# Nuclide record lantheus (company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/companies/lantheus/>
  a schema:Organization ;
  nuclide:kind "company" ;
  schema:identifier "lantheus" ;
  schema:name "Lantheus"@en ;
  schema:alternateName "Progenics Pharmaceuticals, Inc."@en, "Progenics"@en, "Molecular Insight Pharmaceuticals, Inc."@en, "Molecular Insight Pharmaceuticals"@en ;
  schema:description "Lantheus makes Pylarify, the leading PSMA PET agent, with a new TruVu formulation approved in March 2026."@en ;
  schema:url <https://nuclide.cc/companies/lantheus/>, <https://www.lantheus.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.lantheus.com> ;
  schema:addressCountry "US" ;
  nuclide:related <https://nuclide.cc/isotopes/f-18/>, <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/i-131/>, <https://nuclide.cc/isotopes/sm-153/> ;
  nuclide:drugs <https://nuclide.cc/drugs/pylarify/>, <https://nuclide.cc/drugs/i131-mibg/> ;
  nuclide:companies <https://nuclide.cc/companies/evergreen-theragnostics/> ;
  nuclide:trials <https://nuclide.cc/trials/nct06298916/>, <https://nuclide.cc/trials/nct07357519/> .